Skip to content

Clinical trials

Phase 1/2 Immunoglobulin Light-chain Amyloidosis trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Immunoglobulin Light-chain Amyloidosis Phase: Phase 1/2 Clear all

23 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20051
20071
20082
20091
20121
20131
20173
20181
20211
20221
20244
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed15
Recruiting3
Active, not recruiting2
Withdrawn2
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Boston Medical Center2
Fred Hutchinson Cancer Center2
Alexion Pharmaceuticals, Inc.1
Alfred Chung, MD1
Asan Medical Center1
Cancer Treatment Centers of America1
Columbia University1
Dana-Farber Cancer Institute1
Icahn School of Medicine at Mount Sinai1
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Immunoglobulin Light-chain Amyloidosis23
Amyloidosis10
Multiple Myeloma7
Burkitt Lymphoma6
Hodgkin Disease6
Leukemia, Biphenotypic, Acute6
Leukemia, Lymphocytic, Chronic, B-Cell6
Leukemia, Myeloid, Acute6
Leukemia, Myelomonocytic, Chronic6
Lymphoma, B-Cell, Marginal Zone6

Trials

Showing 26 to 23 of 23. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.